gip/glp-1 agonists The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Dual GIP/GLP-1 receptor agonists: New

The FDA has issued warnings about unapproved GLP-1 drugs circulating online - counterfeit, compounded, or mislabeled as research use only. When access to legitimate GLP-1 clinical trials is limited - by geography, logistics, or site capacity - progress slows

FRIDAY, Aug

CONTRIBUTED BY REAL CHEMISTRY | BY RITA GLAZE-ROWE ALABAMA A new study on behalf of Real Chemistry has identified which state Medicaid programs cover GLP-1s.The growing popularity of GLP-1 receptor agonists including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly has added fuel to an already fiery []

Furthermore, post hoc subgroup analyses of cardiovascular outcome trials have suggested a greater cardiorenal protection in patients treated with a combination versus either monotherapy